Novo Nordisk vs. Rio Biopharmaceuticals: Liraglutide Patent Dispute Dismissed
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Novo Nordisk A/S v. Rio Biopharmaceuticals, Inc. |
| Case Number | 1:24-cv-00330 (D.N.J.) |
| Court | U.S. District Court for the District of New Jersey |
| Duration | Jan 2024 – Jul 2024 192 days |
| Outcome | Plaintiff Dismissal — Without Prejudice |
| Patents at Issue | |
| Accused Products | Rio’s Liraglutide Injection 18 mg/3 ml (6 mg/ml) Prefilled Pens |
Case Overview
The Parties
⚖️ Plaintiff
Danish multinational pharmaceutical company, originator and patent holder of liraglutide, with a substantial GLP-1 receptor agonist patent portfolio.
🛡️ Defendant
Generic drug applicant seeking FDA approval to manufacture, use, and sell a generic liraglutide solution for injection.
Patents at Issue
This landmark Hatch-Waxman case involved two U.S. patents protecting core aspects of liraglutide’s pharmaceutical composition and formulation. These foundational patents represent significant barriers to generic entry in the GLP-1 agonist market.
- • U.S. Patent No. 8,114,833 — directed to liraglutide compositions and pharmaceutical formulations
- • U.S. Patent No. 9,265,893 — covering related liraglutide formulation and therapeutic use claims
Developing a generic drug?
Check for patent risks against foundational compound and formulation patents before launch.
The Verdict & Legal Analysis
Outcome
The action was **dismissed without prejudice** pursuant to a stipulated agreement between Novo Nordisk and Rio Biopharmaceuticals, filed as Document 36 on July 29, 2024. Each party agreed to bear its own attorneys’ fees and costs. No damages were awarded, and no injunctive relief was issued.
Key Legal Issues
The infringement action was triggered classically under 35 U.S.C. § 271(e)(2) — the Hatch-Waxman artificial act of infringement created by filing an ANDA with a Paragraph IV certification. No adjudicated findings of validity or infringement were made; the parties resolved the dispute before the court reached substantive merits. The preservation of Rio’s Paragraph IV certification and the absence of any requirement to abandon the ANDA suggest a confidential licensing or entry date agreement, common in Hatch-Waxman settlements, was reached.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical development. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this pharmaceutical litigation.
- View all related GLP-1 patents in this technology space
- See which companies are most active in pharma IP
- Understand formulation claim construction patterns
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own generic drug or formulation.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Liraglutide Compositions & Formulations
2 Key Patents at Issue
In GLP-1 drug space
Design-Around Options
Difficult for core compound claims
✅ Key Takeaways
Dismissed-without-prejudice settlements preserve re-assertion rights — a critical strategic tool in multi-ANDA pharmaceutical litigation.
Search related case law →Allowing Paragraph IV certifications to stand in settlement reflects calculated risk tolerance by originators protecting high-value portfolios.
Explore precedents →Frequently Asked Questions
The case involved U.S. Patent Nos. 8,114,833 and 9,265,893, both directed to liraglutide pharmaceutical compositions and related formulations.
The parties reached a negotiated resolution before trial. A dismissal without prejudice preserves Novo Nordisk’s right to re-assert the patents if warranted, while allowing Rio to maintain its ANDA and Paragraph IV certification.
The settlement does not block FDA approval of Rio’s ANDA. The specific terms governing any authorized entry date are not publicly disclosed, but Rio retains its path to eventual generic market entry.
Ready to Strengthen Your Pharma Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER Case No. 1:24-cv-00330
- U.S. Patent No. 8,114,833 on USPTO Patent Center
- U.S. Patent No. 9,265,893 on USPTO Patent Center
- Cornell Legal Information Institute — 35 U.S.C. § 271(e)(2)
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.